Untitled
Loading...
Date
2014
Journal Title
Journal ISSN
Volume Title
Type
Publisher
Series Info
Doi
Scientific Journal Rankings
Abstract
Inflammatory breast cancer (IBC) is a highly metastatic and fatal form of breast cancer. In fact, IBC is characterized by specific morphological, phenotypic, and biological properties that distinguish it from non-IBC. The aggressive behavior of IBC being more common among young women and the low survival rate alarmed researchers to explore the disease biology. Despite the basic and translational studies needed to understand IBC disease biology and identify specific biomarkers, studies are limited by few available IBC cell lines, experimental models, and paucity of patient samples. Above all, in the last decade, researchers were able to identify new factors that may play a crucial role in IBC progression. Among identified factors are cytokines, chemokines, growth factors, and proteases. In addition, viral infection was also suggested to participate in the etiology of IBC disease. In this review, we present novel factors suggested by different studies to contribute to the etiology of IBC and the proposed new therapeutic insights.
Description
MSA Google Scholar
Keywords
Citation
B.T. Lee, N. Tannenbaum Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of Memorial Hospital Surg Gynecol Obste, 39 (1924), pp. 580-595 View Record in ScopusGoogle Scholar [2] G. Taylor, A. Meltzer “Inflammatory carcinoma” of the breast Am J Cancer, 33 (1938), pp. 33-49 CrossRefView Record in ScopusGoogle Scholar [3] F.M. Robertson, M. Bondy, W. Yang, H. Yamauchi, S. Wiggins, S. Kamrudin, et al. Inflammatory breast cancer: the disease, the biology, the treatment CA Cancer J Clin, 60 (6) (2010), pp. 351-375 CrossRefView Record in ScopusGoogle Scholar [4] K.W. Hance, W.F. Anderson, S.S. Devesa, H.A. Young, P.H. Levine Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute J Natl Cancer Inst, 97 (13) (2005), pp. 966-975 CrossRefView Record in ScopusGoogle Scholar [5] C. Schairer, L.M. Brown, P.L. Mai Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer Breast Cancer Res Treat, 129 (1) (2011), pp. 117-124 CrossRefView Record in ScopusGoogle Scholar [6] S.I. Labidi, K. Mrad, A. Mezlini, M.A. Ouarda, J.D. Combes, M. Ben Abdallah Inflammatory breast cancer in Tunisia in the era of multimodality therapy Ann Oncol, 19 (3) (2008), pp. 473-480 ArticleDownload PDFView Record in ScopusGoogle Scholar [7] S. Dawood, M. Cristofanilli Inflammatory breast cancer: what progress have we made? Oncology (Williston Park), 25 (3) (2011), pp. 264-270 273 Google Scholar [8] C. Schairer, A.S. Soliman, S. Omar, H. Khaled, S. Eissa, F.B. Ayed, et al. Assessment of diagnosis of inflammatory breast cancer cases at two cancer centers in Egypt and Tunisia Cancer Med, 2 (2) (2013), pp. 178-184 CrossRefView Record in ScopusGoogle Scholar [9] N. Mourali, L.R. Muenz, F. Tabbane, S. Belhassen, J. Bahi, P.H. Levine Epidemiologic features of rapidly progressing breast cancer in Tunisia Cancer, 46 (12) (1980), pp. 2741-2746 View Record in ScopusGoogle Scholar [10] J. Costa, B.L. Webber, P.H. Levine, L. Muenz, G.T. O’Conor, F. Tabbane, et al. Histopathological features of rapidly progressing breast carcinoma in Tunisia: a study of 94 cases Int J Cancer, 30 (1) (1982), pp. 35-37 CrossRefView Record in ScopusGoogle Scholar [11] S. Dawood, S.D. Merajver, P. Viens, P.B. Vermeulen, S.M. Swain, T.A. Buchholz, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment Ann Oncol, 22 (3) (2010), pp. 515-523 Google Scholar [12] S. Chang, S.L. Parker, T. Pham, A.U. Buzdar, S.D. Hursting Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992 Cancer, 82 (12) (1998), pp. 2366-2372 View Record in ScopusGoogle Scholar [13] M. Cristofanilli, A.U. Buzdar, G.N. Hortobagyi Update on the management of inflammatory breast cancer Oncologist, 8 (2) (2003), pp. 141-148 View Record in ScopusGoogle Scholar [14] F. Lerebours, I. Bieche, R. Lidereau Update on inflammatory breast cancer Breast Cancer Res, 7 (2) (2005), pp. 52-58 View Record in ScopusGoogle Scholar [15] J.M. Walshe, S.M. Swain Clinical aspects of inflammatory breast cancer Breast Dis, 22 (2005), pp. 35-44 View Record in ScopusGoogle Scholar [16] H. Yamauchi, W.A. Woodward, V. Valero, R.H. Alvarez, A. Lucci, T.A. Buchholz, et al. Inflammatory breast cancer: what we know and what we need to learn Oncologist, 17 (7) (2012), pp. 891-899 CrossRefView Record in ScopusGoogle Scholar [17] S.J. Van Laere, N.T. Ueno, P. Finetti, P.B. Vermeulen, A. Lucci, F.M. Robertson, et al. Uncovering the molecular secrets of Inflammatory Breast Cancer biology: an integrated analysis of three distinct Affymetrix gene expression data sets Clin Cancer Res, 19 (17) (2013), pp. 4685-4696 CrossRefView Record in ScopusGoogle Scholar [18] J.C. Delarue, F. May-Levin, H. Mouriesse, G. Contesso, H. Sancho-Garnier Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast Br J Cancer, 44 (6) (1981), pp. 911-916 CrossRefView Record in ScopusGoogle Scholar [19] I.A. Jaiyesimi, A.U. Buzdar, G. Hortobagyi Inflammatory breast cancer: a review J Clin Oncol, 10 (6) (1992), pp. 1014-1024 View Record in ScopusGoogle Scholar [20] T. Palangie, V. Mosseri, J. Mihura, F. Campana, P. Beuzeboc, T. Dorval, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications Eur J Cancer, 30A (7) (1994), pp. 921-927 ArticleDownload PDFView Record in ScopusGoogle Scholar [21] J.A. Zell, W.Y. Tsang, T.H. Taylor, R.S. Mehta, H. Anton-Culver Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry Breast Cancer Res, 11 (1) (2009), p. R9 Google Scholar [22] K.L. van Golen, S. Davies, Z.F. Wu, Y. Wang, C.D. Bucana, H. Root, et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype Clin Cancer Res, 5 (9) (1999), pp. 2511-2519 View Record in ScopusGoogle Scholar [23] C.G. Kleer, Y. Zhang, Q. Pan, K.L. van Golen, Z.F. Wu, D. Livant, et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer Oncogene, 21 (20) (2002), pp. 3172-3180 CrossRefView Record in ScopusGoogle Scholar [24] Y. Gong Pathologic aspects of inflammatory breast cancer: part 2. Biologic insights into its aggressive phenotype Semin Oncol, 35 (1) (2008), pp. 33-40 ArticleDownload PDFView Record in ScopusGoogle Scholar [25] C.G. Kleer, K.L. van Golen, T. Braun, S.D. Merajver Persistent E-cadherin expression in inflammatory breast cancer Mod Pathol, 14 (5) (2001), pp. 458-464 View Record in ScopusGoogle Scholar [26] P. Bonnier, C. Charpin, C. Lejeune, S. Romain, N. Tubiana, B. Beedassy, et al. Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer, 62 (4) (1995), pp. 382-385 CrossRefView Record in ScopusGoogle Scholar [27] P.J. Kowalski, M.A. Rubin, C.G. Kleer E-cadherin expression in primary carcinomas of the breast and its distant metastases Breast Cancer Res, 5 (6) (2003), pp. R217-R222 Google Scholar [28] C.G. Kleer, Y. Zhang, Q. Pan, G. Gallagher, M. Wu, Z.F. Wu, et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer Breast Cancer Res, 6 (2) (2004) R110-5 Google Scholar [29] K.L. van Golen, L. Bao, M.M. DiVito, Z. Wu, G.C. Prendergast, S.D. Merajver Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor Mol Cancer Ther, 1 (8) (2002), pp. 575-583 View Record in ScopusGoogle Scholar [30] K.L. van Golen, L.W. Bao, Q. Pan, F.R. Miller, Z.F. Wu, S.D. Merajver Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer Clin Exp Metast, 19 (4) (2002), pp. 301-311 View Record in ScopusGoogle Scholar [31] K.L. van Golen, Z.F. Wu, X.T. Qiao, L. Bao, S.D. Merajver RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells Neoplasia, 2 (5) (2000), pp. 418-425 ArticleDownload PDFView Record in ScopusGoogle Scholar [32] K.L. van Golen, Z.F. Wu, X.T. Qiao, L.W. Bao, S.D. Merajver RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype Cancer Res, 60 (20) (2000), pp. 5832-5838 View Record in ScopusGoogle Scholar [33] G.G. Van den Eynden, I. Van der Auwera, S. Van Laere, C.G. Colpaert, P. van Dam, S. Merajver, et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer Breast Cancer Res Treat, 85 (1) (2004), pp. 13-22 View Record in ScopusGoogle Scholar [34] C.G. Kleer, K.L. van Golen, Y. Zhang, Z.F. Wu, M.A. Rubin, S.D. Merajver Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability Am J Pathol, 160 (2) (2002), pp. 579-584 ArticleDownload PDFView Record in ScopusGoogle Scholar [35] C.G. Kleer, K.A. Griffith, M.S. Sabel, G. Gallagher, K.L. van Golen, Z.F. Wu, et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast Breast Cancer Res Treat, 93 (2) (2005), pp. 101-110 CrossRefView Record in ScopusGoogle Scholar [36] M. Wu, Z.F. Wu, C. Kumar-Sinha, A. Chinnaiyan, S.D. Merajver RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells Breast Cancer Res Treat, 84 (1) (2004), pp. 3-12 View Record in ScopusGoogle Scholar [37] F. Lerebours, G. Cizeron-Clairac, A. Susini, S. Vacher, E. Mouret-Fourme, C. Belichard, et al. miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness Int J Cancer, 133 (7) (2013), pp. 1614-1623 CrossRefView Record in ScopusGoogle Scholar [38] D.T. Tsoi, C. Rowsell, C. McGregor, C.M. Kelly, S. Verma, K.I. Pritchard Disseminated tumor embolism from breast cancer leading to multiorgan failure J Clin Oncol, 28 (12) (2010) e180-3 Google Scholar [39] J. Morales, M.L. Alpaugh Gain in cellular organization of inflammatory breast cancer: a 3D in vitro model that mimics the in vivo metastasis BMC Cancer, 9 (2009), p. 462 CrossRefView Record in ScopusGoogle Scholar [40] S. Mahooti, K. Porter, M.L. Alpaugh, Y. Ye, Y. Xiao, S. Jones, et al. Breast carcinomatous tumoral emboli can result from encircling lymphovasculogenesis rather than lymphovascular invasion Oncotarget, 1 (2) (2010), pp. 131-147 View Record in ScopusGoogle Scholar [41] Y. Xiao, Y. Ye, K. Yearsley, S. Jones, S.H. Barsky The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype Am J Pathol, 173 (2) (2008), pp. 561-574 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar [42] M.M. Mohamed Monocytes conditioned media stimulate fibronectin expression and spreading of inflammatory breast cancer cells in three-dimensional culture: a mechanism mediated by IL-8 signaling pathway Cell Commun Signal, 10 (1) (2012), p. 3 CrossRefView Record in ScopusGoogle Scholar [43] H.L. Lehman, E.J. Dashner, M. Lucey, P. Vermeulen, L. Dirix, S. Van Laere, et al. Modeling and characterization of inflammatory breast cancer emboli grown in vitro Int J Cancer (2012) Google Scholar [44] J.W. Pollard Macrophages define the invasive microenvironment in breast cancer J Leukoc Biol, 84 (3) (2008), pp. 623-630 CrossRefView Record in ScopusGoogle Scholar [45] R.A. Mukhtar, O. Nseyo, M.J. Campbell, L.J. Esserman Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics Expert Rev Mol Diagn, 11 (1) (2011), pp. 91-100 CrossRefView Record in ScopusGoogle Scholar [46] S. Aaltomaa, P. Lipponen, M. Eskelinen, V.M. Kosma, S. Marin, E. Alhava, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer Eur J Cancer, 28A (4–5) (1992), pp. 859-864 ArticleDownload PDFView Record in ScopusGoogle Scholar [47] S.N. Georgiannos, A. Renaut, A.W. Goode, M. Sheaff The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers, the role of the major histocompatibility complex in cell-mediated immune mechanisms, and their association with prognostic indicators Surgery, 134 (5) (2003), pp. 827-834 ArticleDownload PDFView Record in ScopusGoogle Scholar [48] J.W. Pollard Trophic macrophages in development and disease Nat Rev Immunol, 9 (4) (2009), pp. 259-270 CrossRefView Record in ScopusGoogle Scholar [49] L.S. Ojalvo, W. King, D. Cox, J.W. Pollard High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors Am J Pathol, 174 (3) (2009), pp. 1048-1064 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar [50] D.M. Mosser, J.P. Edwards Exploring the full spectrum of macrophage activation Nat Rev Immunol, 8 (12) (2008), pp. 958-969 CrossRefView Record in ScopusGoogle Scholar [51] C.E. Lewis, R. Leek, A. Harris, J.O. McGee Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages J Leukoc Biol, 57 (5) (1995), pp. 747-751 CrossRefView Record in ScopusGoogle Scholar [52] R.D. Leek, C.E. Lewis, R. Whitehouse, M. Greenall, J. Clarke, A.L. Harris Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma Cancer Res, 56 (20) (1996), pp. 4625-4629 View Record in ScopusGoogle Scholar [53] J. Condeelis, J.W. Pollard Macrophages: obligate partners for tumor cell migration, invasion, and metastasis Cell, 124 (2) (2006), pp. 263-266 ArticleDownload PDFView Record in ScopusGoogle Scholar [54] A. Mantovani, T. Schioppa, C. Porta, P. Allavena, A. Sica Role of tumor-associated macrophages in tumor progression and invasion Cancer Metast Rev, 25 (3) (2006), pp. 315-322 CrossRefView Record in ScopusGoogle Scholar [55] T. Hagemann, J. Wilson, H. Kulbe, N.F. Li, D.A. Leinster, K. Charles, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK J Immunol, 175 (2) (2005), pp. 1197-1205 CrossRefView Record in ScopusGoogle Scholar [56] L.O. Gonzalez, I. Pidal, S. Junquera, M.D. Corte, J. Vazquez, J.C. Rodriguez, et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse Br J Cancer, 97 (7) (2007), pp. 957-963 CrossRefView Record in ScopusGoogle Scholar [57] C. O’Sullivan, C.E. Lewis, A.L. Harris, J.O. McGee Secretion of epidermal growth factor by macrophages associated with breast carcinoma Lancet, 342 (8864) (1993), pp. 148-149 ArticleDownload PDFView Record in ScopusGoogle Scholar [58] S. Van Laere, I. Van der Auwera, G.G. Van den Eynden, S.B. Fox, F. Bianchi, A.L. Harris, et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis Breast Cancer Res Treat, 93 (3) (2005), pp. 237-246 CrossRefView Record in ScopusGoogle Scholar [59] T. Compton, E.A. Kurt-Jones, K.W. Boehme, J. Belko, E. Latz, D.T. Golenbock, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2 J Virol, 77 (8) (2003), pp. 4588-4596 View Record in ScopusGoogle Scholar [60] C.E. Lewis, J.W. Pollard Distinct role of macrophages in different tumor microenvironments Cancer Res, 66 (2) (2006), pp. 605-612 View Record in ScopusGoogle Scholar [61] M.M. Mohamed, D. Cavallo-Medved, B.F. Sloane Human monocytes augment invasiveness and proteolytic activity of inflammatory breast cancer Biol Chem, 389 (8) (2008), pp. 1117-1121 View Record in ScopusGoogle Scholar [62] M.A. Nouh, M.M. Mohamed, M. El-Shinawi, M.A. Shaalan, D. Cavallo-Medved, H.M. Khaled, et al. Cathepsin B: a potential prognostic marker for inflammatory breast cancer J Transl Med, 9 (2011), p. 1 CrossRefGoogle Scholar [63] D. Al-Raawi, H. Abu-El-Zahab, M. El-Shinawi, M.M. Mohamed Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer Int J Clin Exp Med, 4 (4) (2011), pp. 265-275 View Record in ScopusGoogle Scholar [64] M.M. Mohamed, B.F. Sloane Cysteine cathepsins: multifunctional enzymes in cancer Nat Rev Cancer, 6 (10) (2006), pp. 764-775 CrossRefView Record in ScopusGoogle Scholar [65] M. Lee, R. Fridman, S. Mobashery Extracellular proteases as targets for treatment of cancer metastases Chem Soc Rev, 33 (7) (2004), pp. 401-409 View Record in ScopusGoogle Scholar [66] G. Opdenakker, J. Van Damme Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer Cytokine, 4 (4) (1992), pp. 251-258 ArticleDownload PDFView Record in ScopusGoogle Scholar [67] A.E. Place, S. Jin Huh, K. Polyak The microenvironment in breast cancer progression: biology and implications for treatment Breast Cancer Res, 13 (6) (2011), p. 227 Google Scholar [68] M. Sameni, A. Anbalagan, M.B. Olive, K. Moin, R.R. Mattingly, B.F. Sloane MAME models for 4D live-cell imaging of tumor: microenvironment interactions that impact malignant progression J Vis Exp (60) (2012) Google Scholar [69] J.M. Rothberg, M. Sameni, K. Moin, B.F. Sloane Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment Biochim Biophys Acta, 1824 (1) (2012), pp. 123-132 ArticleDownload PDFView Record in ScopusGoogle Scholar [70] G.G. Van den Eynden, S.J. Van Laere, I. Van der Auwera, S.D. Merajver, E.A. Van Marck, P. van Dam, et al. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer Breast Cancer Res Treat, 95 (3) (2006), pp. 219-228 CrossRefView Record in ScopusGoogle Scholar [71] D. Cavallo-Medved, J. Mai, J. Dosescu, M. Sameni, B.F. Sloane Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells J Cell Sci, 118 (Pt 7) (2005), pp. 1493-1503 CrossRefView Record in ScopusGoogle Scholar [72] D. Cavallo-Medved, D. Rudy, G. Blum, M. Bogyo, D. Caglic, B.F. Sloane Live-cell imaging demonstrates extracellular matrix degradation in association with active cathepsin B in caveolae of endothelial cells during tube formation Exp Cell Res, 315 (7) (2009), pp. 1234-1246 ArticleDownload PDFView Record in ScopusGoogle Scholar [73] D. Cavallo-Medved, B.F. Sloane Cell-surface cathepsin B: understanding its functional significance Curr Top Dev Biol, 54 (2003), pp. 313-341 ArticleDownload PDFView Record in ScopusGoogle Scholar [74] W.P. Ren, B.F. Sloane Cathepsins D and B in breast cancer Cancer Treat Res, 83 (1996), pp. 325-352 CrossRefView Record in ScopusGoogle Scholar [75] H. Kobayashi, N. Moniwa, M. Sugimura, H. Shinohara, H. Ohi, T. Terao Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes Biochim Biophys Acta, 1178 (1) (1993), pp. 55-62 ArticleDownload PDFView Record in ScopusGoogle Scholar [76] B.C. Victor, A. Anbalagan, M.M. Mohamed, B.F. Sloane, D. Cavallo-Medved Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion Breast Cancer Res, 13 (6) (2011), p. R115 Google Scholar [77] M.D. Sternlicht, Z. Werb How matrix metalloproteinases regulate cell behavior Annu Rev Cell Dev Biol, 17 (2001), pp. 463-516 CrossRefView Record in ScopusGoogle Scholar [78] P. Vihinen, R. Ala-aho, V.M. Kahari Matrix metalloproteinases as therapeutic targets in cancer Curr Cancer Drug Targets, 5 (3) (2005), pp. 203-220 CrossRefView Record in ScopusGoogle Scholar [79] A. Kohrmann, U. Kammerer, M. Kapp, J. Dietl, J. Anacker Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature BMC Cancer, 9 (2009), p. 188 Google Scholar [80] S. Patel, G. Sumitra, B.C. Koner, A. Saxena Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression Clin Biochem, 44 (10–11) (2011), pp. 869-872 ArticleDownload PDFView Record in ScopusGoogle Scholar [81] J.M. Ray, W.G. Stetler-Stevenson The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis Eur Respir J, 7 (11) (1994), pp. 2062-2072 View Record in ScopusGoogle Scholar [82] M.J. Duffy, T.M. Maguire, A. Hill, E. McDermott, N. O’Higgins Metalloproteinases: role in breast carcinogenesis, invasion and metastasis Breast Cancer Res, 2 (4) (2000), pp. 252-257 View Record in ScopusGoogle Scholar [83] A. Noel, A. Gutierrez-Fernandez, N.E. Sounni, N. Behrendt, E. Maquoi, I.K. Lund, et al. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment Front Pharmacol, 3 (2012), p. 140 Google Scholar [84] S. Noh, J.J. Jung, M. Jung, T.S. Kim, C.H. Park, S.J. Lim, et al. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer Hepatogastroenterology, 58 (112) (2011), pp. 2015-2019 View Record in ScopusGoogle Scholar [85] U. Damodharan, R. Ganesan, U.C. Radhakrishnan Expression of MMP2 and MMP9 (gelatinases A and B) in human colon cancer cells Appl Biochem Biotechnol, 165 (5–6) (2011), pp. 1245-1252 CrossRefView Record in ScopusGoogle Scholar [86] C. Gialeli, A.D. Theocharis, N.K. Karamanos Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting FEBS J, 278 (1) (2011), pp. 16-27 CrossRefView Record in ScopusGoogle Scholar [87] N.E. Sounni, A. Noel Membrane type-matrix metalloproteinases and tumor progression Biochimie, 87 (3–4) (2005), pp. 329-342 ArticleDownload PDFView Record in ScopusGoogle Scholar [88] A. Noel, C. Maillard, N. Rocks, M. Jost, V. Chabottaux, N.E. Sounni, et al. Membrane associated proteases and their inhibitors in tumour angiogenesis J Clin Pathol, 57 (6) (2004), pp. 577-584 View Record in ScopusGoogle Scholar [89] R.C. Figueira, L.R. Gomes, J.S. Neto, F.C. Silva, I.D. Silva, M.C. Sogayar Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential BMC Cancer, 9 (2009), p. 20 Google Scholar [90] W.G. Jiang, G. Davies, T.A. Martin, C. Parr, G. Watkins, M.D. Mason, et al. Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells Int J Mol Med, 17 (4) (2006), pp. 583-590 View Record in ScopusGoogle Scholar [91] O.C. Kousidou, A.E. Roussidis, A.D. Theocharis, N.K. Karamanos Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential Anticancer Res, 24 (6) (2004), pp. 4025-4030 View Record in ScopusGoogle Scholar [92] P.J. de Andres, J.C. Illera, S. Caceres, L. Diez, M.D. Perez-Alenza, L. Pena Increased levels of interleukins 8 and 10 as findings of canine inflammatory mammary cancer Vet Immunol Immunopathol (2012) Google Scholar [93] B.G. Debeb, E.N. Cohen, K. Boley, E.M. Freiter, L. Li, F.M. Robertson, et al. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells Breast Cancer Res Treat, 134 (2) (2012), pp. 495-510 CrossRefView Record in ScopusGoogle Scholar [94] I. Bieche, F. Lerebours, S. Tozlu, M. Espie, M. Marty, R. Lidereau Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature Clin Cancer Res, 10 (20) (2004), pp. 6789-6795 CrossRefView Record in ScopusGoogle Scholar [95] D. Drygin, C.B. Ho, M. Omori, J. Bliesath, C. Proffitt, R. Rice, et al. Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer Biochem Biophys Res Commun, 415 (1) (2011), pp. 163-167 ArticleDownload PDFView Record in ScopusGoogle Scholar [96] J. Kurebayashi Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications Breast Cancer, 7 (2) (2000), pp. 124-129 View Record in ScopusGoogle Scholar [97] H. Knupfer, R. Preiss Significance of interleukin-6 (IL-6) in breast cancer (review) Breast Cancer Res Treat, 102 (2) (2007), pp. 129-135 CrossRefView Record in ScopusGoogle Scholar [98] K. Arihiro, H. Oda, M. Kaneko, K. Inai Cytokines facilitate chemotactic motility of breast carcinoma cells Breast Cancer, 7 (3) (2000), pp. 221-230 View Record in ScopusGoogle Scholar [99] F. Lerebours, S. Vacher, C. Andrieu, M. Espie, M. Marty, R. Lidereau, et al. NF-kappa B genes have a major role in inflammatory breast cancer BMC Cancer, 8 (2008), p. 41 Google Scholar [100] E. Charafe-Jauffret, C. Ginestier, F. Iovino, J. Wicinski, N. Cervera, P. Finetti, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature Cancer Res, 69 (4) (2009), pp. 1302-1313 CrossRefView Record in ScopusGoogle Scholar [101] S. Liu, C. Ginestier, S.J. Ou, S.G. Clouthier, S.H. Patel, F. Monville, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks Cancer Res, 71 (2) (2011), pp. 614-624 CrossRefView Record in ScopusGoogle Scholar [102] S. Giampieri, C. Manning, S. Hooper, L. Jones, C.S. Hill, E. Sahai Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility Nat Cell Biol, 11 (11) (2009), pp. 1287-1296 CrossRefView Record in ScopusGoogle Scholar [103] S. Giampieri, S. Pinner, E. Sahai Intravital imaging illuminates transforming growth factor beta signaling switches during metastasis Cancer Res, 70 (9) (2010), pp. 3435-3439 View Record in ScopusGoogle Scholar [104] W.K. Glenn, B. Heng, W. Delprado, B. Iacopetta, N.J. Whitaker, J.S. Lawson Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer PLoS ONE, 7 (11) (2012), p. e48788 CrossRefGoogle Scholar [105] Y. Wang, J.F. Holland, I.J. Bleiweiss, S. Melana, X. Liu, I. Pelisson, et al. Detection of mammary tumor virus env gene-like sequences in human breast cancer Cancer Res, 55 (22) (1995), pp. 5173-5179 View Record in ScopusGoogle Scholar [106] B. Liu, Y. Wang, S.M. Melana, I. Pelisson, V. Najfeld, J.F. Holland, et al. Identification of a proviral structure in human breast cancer Cancer Res, 61 (4) (2001), pp. 1754-1759 View Record in ScopusGoogle Scholar [107] S. Fawzy, M. Sallam, N.M. Awad Detection of Epstein-Barr virus in breast carcinoma in Egyptian women Clin Biochem, 41 (7–8) (2008), pp. 486-492 ArticleDownload PDFView Record in ScopusGoogle Scholar [108] L.E. Harkins, L.A. Matlaf, L. Soroceanu, K. Klemm, W.J. Britt, W. Wang, et al. Detection of human cytomegalovirus in normal and neoplastic breast epithelium Herpesviridae, 1 (1) (2010), p. 8 CrossRefView Record in ScopusGoogle Scholar [109] B.G. Pogo, JF.. Holland, P.H. Levine Human mammary tumor virus in inflammatory breast cancer Cancer, 116 (11 Suppl) (2010), pp. 2741-2744 CrossRefView Record in ScopusGoogle Scholar [110] A.S. Soliman, M. Banerjee, A.C. Lo, K. Ismail, A. Hablas, I.A. Seifeldin, et al. High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah, Egypt Egypt. Breast J, 15 (4) (2009), pp. 432-434 CrossRefView Record in ScopusGoogle Scholar [111] A.S. Soliman, A.C. Lo, M. Banerjee, N. El-Ghawalby, H.M. Khaled, S. Bayoumi, et al. Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution Carcinogenesis, 28 (8) (2007), pp. 1794-1799 CrossRefView Record in ScopusGoogle Scholar [112] A.S. Soliman, S.V. Vulimiri, H.E. Kleiner, J. Shen, S. Eissa, M. Morad, et al. High levels of oxidative DNA damage in lymphocyte DNA of premenopausal breast cancer patients from Egypt Int J Environ Health Res, 14 (2) (2004), pp. 121-134 View Record in ScopusGoogle Scholar [113] A.S. Soliman, X. Wang, J.D. Stanley, N. El-Ghawalby, M.L. Bondy, F. Ezzat, et al. Geographical clustering of pancreatic cancers in the Northeast Nile Delta region of Egypt Arch Environ Contam Toxicol, 51 (1) (2006), pp. 142-148 CrossRefView Record in ScopusGoogle Scholar [114] S. Fiorentini, A. Luganini, V. Dell’Oste, B. Lorusso, E. Cervi, F. Caccuri, et al. Human cytomegalovirus productively infects lymphatic endothelial cells and induces a secretome that promotes angiogenesis and lymphangiogenesis through interleukin-6 and granulocyte-macrophage colony-stimulating factor J Gen Virol, 92 (Pt 3) (2011), pp. 650-660 CrossRefView Record in ScopusGoogle Scholar [115] L.K. Juckem, K.W. Boehme, A.L. Feire, T. Compton Differential initiation of innate immune responses induced by human cytomegalovirus entry into fibroblast cells J Immunol, 180 (7) (2008), pp. 4965-4977 CrossRefView Record in ScopusGoogle Scholar [116] M. Michaelis, H.W. Doerr, J. Cinatl The story of human cytomegalovirus and cancer: increasing evidence and open questions Neoplasia, 11 (1) (2009), pp. 1-9 ArticleDownload PDFView Record in ScopusGoogle Scholar [117] C.P. Fagundes, R. Glaser, C.M. Alfano, J.M. Bennett, S.P. Povoski, A.M. Lipari, et al. Fatigue and herpesvirus latency in women newly diagnosed with breast cancer Brain Behav Immun (2011) Google Scholar [118] O. Breathnach, P. Donnellan, D. Collins, W. McNicholas, J. Crown Cytomegalovirus pneumonia in a patient with breast cancer on chemotherapy: case report and review of the literature Ann Oncol, 10 (4) (1999), pp. 461-465 ArticleDownload PDFView Record in ScopusGoogle Scholar [119] M.C. Cheeran, S. Hu, S.L. Yager, G. Gekker, P.K. Peterson, J.R. Lokensgard Cytomegalovirus induces cytokine and chemokine production differentially in microglia and astrocytes: antiviral implications J Neurovirol, 7 (2) (2001), pp. 135-147 View Record in ScopusGoogle Scholar [120] E.T. Roberts, M.N. Haan, J.B. Dowd, A.E. Aiello Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up Am J Epidemiol, 172 (4) (2010), pp. 363-371 CrossRefView Record in ScopusGoogle Scholar [121] M. El-Shinawi, H.T. Mohamed, E.A. El-Ghonaimy, M. Tantawy, A. Younis, R.J. Schneider, et al. Human cytomegalovirus infection enhances NF-kappaB/p65 signaling in inflammatory breast cancer patients PLoS ONE, 8 (2) (2013), p. e55755 CrossRefGoogle Scholar [122] M. Cristofanilli, A.M. Gonzalez-Angulo, A.U. Buzdar, S.-W. Kau, D.K. Frye, G.N. Hortobagyi Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience Clin. Breast Cancer, 4 (6) (2004), pp. 415-419 ArticleDownload PDFView Record in ScopusGoogle Scholar [123] L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch, S. Tjulandin, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort Lancet, 375 (9712) (2010), pp. 377-384 ArticleDownload PDFView Record in ScopusGoogle Scholar [124] J. Hurley, P. Doliny, I. Reis, O. Silva, C. Gomez-Fernandez, P. Velez, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer J Clin Oncol: Off J Am Soc Clin Oncol, 24 (12) (2006), pp. 1831-1838 View Record in ScopusGoogle Scholar [125] L.D. Curcio, E. Rupp, W.L. Williams, D.Z. Chu, K. Clarke, T. Odom-Maryon, et al. Beyond palliative mastectomy in inflammatory breast cancer – a reassessment of margin status Ann Surg Oncol, 6 (3) (1999), pp. 249-254 CrossRefView Record in ScopusGoogle Scholar [126] I.J. Bristol, W.A. Woodward, E.A. Strom, M. Cristofanilli, D. Domain, S.E. Singletary, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer Int J Radiat Oncol Biol Phys, 72 (2) (2008), pp. 474-484 ArticleDownload PDFView Record in ScopusGoogle Scholar [127] R.L. Hillyer, P. Sirinvasin, M. Joglekar, R.A. Sikes, K.L. van Golen, A. Nohe Differential effects of vitamin D treatment on inflammatory and non-inflammatory breast cancer cell lines Clin Exp Metast, 29 (8) (2012), pp. 971-979 CrossRefView Record in ScopusGoogle Scholar [128] L. Kavandi, M.A. Collier, H. Nguyen, V. Syed Progesterone and calcitriol attenuate inflammatory cytokines CXCL1 and CXCL2 in ovarian and endometrial cancer cells J Cell Biochem, 113 (10) (2012), pp. 3143-3152 CrossRefView Record in ScopusGoogle Scholar [129] L.J. Miller, S.H. Kurtzman, K. Anderson, Y. Wang, M. Stankus, M. Renna, et al. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist Cancer Invest, 18 (4) (2000), pp. 293-302 CrossRefView Record in ScopusGoogle Scholar [130] A.G. Pantschenko, I. Pushkar, L.J. Miller, Y.P. Wang, K. Anderson, Z. Peled, et al. In vitro demonstration of breast cancer tumor cell sub-populations based on interleukin-1/tumor necrosis factor induction of interleukin-8 expression Oncol Rep, 10 (4) (2003), pp. 1011-1017 View Record in ScopusGoogle Scholar [131] L.S. Angelo, R. Kurzrock Vascular endothelial growth factor and its relationship to inflammatory mediators Clin Cancer Res, 13 (10) (2007), pp. 2825-2830 CrossRefView Record in ScopusGoogle Scholar [132] Y. Lin, R. Huang, L. Chen, S. Li, Q. Shi, C. Jordan, et al. I